Increased cost of illness among European patients with type 2 diabetes treated with insulin

Abstract

Objectives: To investigate the association between outcomes and different escalating combinations of non-insulin medications vs. insulin.

Methods: Data were taken from the 2013 5EU NHWS, a cross-sectional survey including 62,000 respondents across France, Germany, Italy, Spain, and the UK. Costs were estimated from self-reported work impairment and healthcare visits using average wages and unit costs. Respondents taking antihyperglycemic medications (n = 2894) were compared according to treatment type using unadjusted comparisons followed by regression to adjust for confounders.

Results: Insulin users had the highest costs and worse outcomes, a pattern that remained after adjustment for a range of sociodemographic and disease characteristics. Incremental direct costs were approximately €800. Incremental indirect costs, applicable only to the employed, were larger than incremental direct costs, but were statistically significant only relative to non-insulin monotherapy.

Conclusions: Escalation using oral agents rather than insulin is associated with better quality of life and lower costs, though these relationships may not be causal. Further research is warranted on escalation using oral agents among patients for whom insulin is not required.

Keywords:

• Cost
• diabetes
• insulin therapies
• non-insulin therapies
• work productivity

Transparency

Declaration of funding

This study was funded by Janssen.

Declaration of financial/other relationships

S.N. and M.W.-C. have disclosed that they are employees of Janssen. J.V. has disclosed that he is an employee of Kantar Health, a company that received funding from Janssen to help conduct this study.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

Jan-Samuel Wagner provided writing assistance. Funding for this study was provided to Kantar Health by Janssen.